4basebio Statistics

Total Valuation

4basebio has a market cap or net worth of GBP 110.28 million. The enterprise value is 99.60 million.

Market Cap	110.28M
Enterprise Value	99.60M

Important Dates

The next estimated earnings date is Thursday, May 21, 2026.

Earnings Date	May 21, 2026
Ex-Dividend Date	n/a

Share Statistics

4basebio has 15.48 million shares outstanding. The number of shares has increased by 15.92% in one year.

Current Share Class	15.48M
Shares Outstanding	15.48M
Shares Change (YoY)	+15.92%
Shares Change (QoQ)	+14.52%
Owned by Insiders (%)	14.70%
Owned by Institutions (%)	40.59%
Float	5.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	61.99
PB Ratio	5.81
P/TBV Ratio	6.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.91
EV / Sales	55.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.82

Financial Position

The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.81.

Current Ratio	11.36
Quick Ratio	10.38
Debt / Equity	0.81
Debt / EBITDA	n/a
Debt / FCF	-1.06
Interest Coverage	-18.58

Financial Efficiency

Return on equity (ROE) is -209.34% and return on invested capital (ROIC) is -42.88%.

Return on Equity (ROE)	-209.34%
Return on Assets (ROA)	-39.27%
Return on Invested Capital (ROIC)	-42.88%
Return on Capital Employed (ROCE)	-44.64%
Revenue Per Employee	16,173
Profits Per Employee	-130,991
Employee Count	110
Asset Turnover	0.07
Inventory Turnover	1.54

Taxes

Income Tax	-325,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.19% in the last 52 weeks. The beta is 0.94, so 4basebio's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	-45.19%
50-Day Moving Average	747.10
200-Day Moving Average	955.08
Relative Strength Index (RSI)	29.10
Average Volume (20 Days)	877

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 4basebio had revenue of GBP 1.78 million and -14.41 million in losses. Loss per share was -0.99.

Revenue	1.78M
Gross Profit	1.10M
Operating Income	-15.33M
Pretax Income	-14.73M
Net Income	-14.41M
EBITDA	-14.70M
EBIT	-15.33M
Loss Per Share	-0.99

Full Income Statement

Balance Sheet

The company has 26.11 million in cash and 15.44 million in debt, giving a net cash position of 10.68 million or 0.69 per share.

Cash & Cash Equivalents	26.11M
Total Debt	15.44M
Net Cash	10.68M
Net Cash Per Share	0.69
Equity (Book Value)	18.98M
Book Value Per Share	1.23
Working Capital	26.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -13.77 million and capital expenditures -831,000, giving a free cash flow of -14.60 million.

Operating Cash Flow	-13.77M
Capital Expenditures	-831,000
Free Cash Flow	-14.60M
FCF Per Share	-0.94

Full Cash Flow Statement

Margins

Gross Margin	61.55%
Operating Margin	-861.83%
Pretax Margin	-828.22%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

4basebio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.92%
Shareholder Yield	-15.92%
Earnings Yield	-13.07%
FCF Yield	-13.24%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

4basebio has an Altman Z-Score of 3.22 and a Piotroski F-Score of 3.

Altman Z-Score	3.22
Piotroski F-Score	3